Jubilant Pharmova Ltd's Q4FY25 Quarter Results
- 17 May 2025
Result Summary
- Jubilant Pharmova Ltd reported a 3.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 5.4%.
- Its expenses for the quarter were down by 1.2% QoQ and 7.0% YoY.
- The net profit decreased 161.4% QoQ and decreased 38.5% YoY.
- The earnings per share (EPS) of Jubilant Pharmova Ltd declined at 3.7 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1773.00 | 1830.90 | 1682.45 | -3.2% | 5.4% |
Total Expenses | 1661.20 | 1681.20 | 1785.57 | -1.2% | -7.0% |
Profit Before Tax | -57.10 | 130.80 | -103.12 | -143.7% | -44.6% |
Tax | 8.10 | 29.80 | 14.10 | -72.8% | -42.6% |
Profit After Tax | -61.80 | 100.70 | -100.51 | -161.4% | -38.5% |
Earnings Per Share | -3.70 | 6.40 | -6.20 | -157.8% | -40.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Jubilant Pharmova Ltd is a well-established pharmaceutical company operating within the healthcare sector. The company is primarily engaged in the development and manufacturing of a broad range of pharmaceutical and life sciences products. These include active pharmaceutical ingredients (APIs), generics, specialty pharmaceuticals, and contract research and manufacturing services (CRAMS). As of the latest updates available until October 2023, Jubilant Pharmova has been actively involved in expanding its product portfolio and enhancing its manufacturing capabilities to cater to a growing global demand for healthcare solutions. Specific recent developments or strategic initiatives were not available in the provided data.
Revenue
In the fourth quarter of fiscal year 2025 (Q4FY25), Jubilant Pharmova Ltd reported a total income of ₹1773.00 crores. This reflects a decrease of 3.2% compared to the previous quarter (Q3FY25), where the total income was ₹1830.90 crores. However, on a year-over-year basis, there was an increase of 5.4% compared to the same period in the previous fiscal year (Q4FY24), where the total income was ₹1682.45 crores. This upward trajectory in revenue on a year-over-year basis indicates an overall growth in sales or services provided by the company despite the quarterly decline.
Profitability
During Q4FY25, Jubilant Pharmova Ltd experienced a loss, as indicated by a negative profit after tax (PAT) of ₹-61.80 crores. This represents a significant decline from the profit of ₹100.70 crores reported in Q3FY25, marking a quarter-over-quarter decrease of 161.4%. Compared to the same quarter in the previous fiscal year (Q4FY24), where the company reported a loss of ₹-100.51 crores, there is a year-over-year improvement of 38.5%. The earnings per share (EPS) in Q4FY25 were ₹-3.70, compared to ₹6.40 in Q3FY25 and ₹-6.20 in Q4FY24, reflecting similar trends in profitability metrics. The profit before tax (PBT) was also negative at ₹-57.10 crores in Q4FY25, compared to a positive ₹130.80 crores in Q3FY25, indicating a significant quarter-over-quarter decline.
Operating Metrics
Total expenses for Jubilant Pharmova Ltd in Q4FY25 amounted to ₹1661.20 crores, which is a decrease of 1.2% from the previous quarter (Q3FY25) where total expenses were ₹1681.20 crores. On a year-over-year basis, there was a decline of 7.0% in expenses compared to Q4FY24, which were ₹1785.57 crores. The tax expense for Q4FY25 was ₹8.10 crores, showing a significant reduction of 72.8% from Q3FY25 and a 42.6% decrease from Q4FY24. These changes in expenses and tax indicate adjustments in the company's cost structures and tax obligations over the observed periods. The negative earnings per share (EPS) in Q4FY25 of ₹-3.70 compared to the previous quarter and the same quarter last year, indicates the impact of the profitability decline on shareholder returns.